Boston battens down the hatches for possible stent storm
This article was originally published in Clinica
Boston Scientific CEO James Tobin reported profits that fell by 22% before special charges in the first quarter and warned that, with the likelihood of a further loss of market share in stents for the rest of the year, the company had to "batten down the hatches" to reduce expenditure.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.